Short sellers have built a deeply entrenched position in ARCT ahead of its Q1 2026 results tonight — and the borrow market tells a quietly unusual story for a stock trading at $8.90.
Short interest runs at 21.6% of the free float, one of the most heavily shorted readings in the biotech universe. The ORTEX short score has climbed to 81.9, ranking in just the 2nd percentile across the market — meaning almost no stock is more shorted on a relative basis. Days to cover stand at 20.8, so any covering wave would take weeks to unwind. Yet the short position itself has been slowly retreating: short interest fell roughly 2.1% over the past month, and another 0.8% on the week, suggesting some bears are quietly trimming rather than adding into the print. Borrow remains cheap at 0.88% annualised — well inside what would signal a squeezable setup — and availability is in the moderate range, meaning new shorts face little friction entering the trade.
Options positioning is calm by comparison, and that contrast is notable. The put/call ratio is 0.59, a touch above its 20-day average of 0.54 but only about one standard deviation away — far from the defensive extremes that signal pre-earnings panic. The 52-week PCR range runs from 0.15 to 2.74, so the current reading is actually closer to the bullish end of the historical band. That divergence — heavy short positioning on one hand, and fairly relaxed options hedging on the other — defines the tension heading into tonight's release. The stock is up 3.2% on the week and 8.3% over the past month, a modest recovery that has done nothing to dislodge the bears but equally hasn't attracted fresh put buying.
The bull and bear cases are well-defined. Bulls point to CSL Behring's commercial backing for KOSTAIVE across Asia and Europe, an mRNA COVID-19 vaccine that remains the company's primary near-term revenue driver. A delay in the US BLA filing has paradoxically extended the cash runway for the ARCT-810 OTC programme and the early-stage ARCT-032 CF programme — a silver lining bulls will emphasise. Analysts with buy ratings carry a mean price target around $23, more than 150% above the current price; the return potential figure from the screening data corroborates that gap. Bears, however, point to uncertain commercial viability for ARCT-810, the early-stage nature of the CF programme, and a cash burn that saw operating cash outflows of roughly $147 million on the latest available estimate. The most recent analyst movement came from a B. Riley initiation at Buy with a $22 target in March, while Citigroup's Neutral-rated analyst moved their target to $8 — essentially flat to today's price. That split reflects how far apart the fundamental views remain. Note that several older price targets (Piper Sandler's prior target of $72, Citigroup's prior $49) reflect the stock's much higher levels before a significant de-rating; those figures are not current.
ARK Investment Management added 738,000 shares in April — making it one of the most active institutional movers ahead of this print. That conviction buy from a growth-focused investor sits in direct contrast to the short sellers holding 21.6% of the float. The past two earnings reactions offer a sobering reference point: the March 2026 print produced a 1-day gain of 1.5% that then gave way to a 7.9% decline over five sessions, while the prior event saw a 9.2% one-day drop followed by a further 8.7% slide over the following week.
Tonight's print will test whether the modest pipeline progress and cost discipline are enough to justify the ARK-style conviction — or whether the bears who have held this position for months are right that the runway is shorter than the bulls believe.
See the live data behind this article on ORTEX.
Open ARCT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
